Mesoblast Corporate Update and Financial Results Webcast
November 19 2020 - 4:19PM
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in
allogeneic cellular medicines for inflammatory diseases, will host
a webcast today to provide a corporate update, and report financial
and operational highlights for the first quarter ended September
30, 2020 (FY2021).
Conference Call Details The
webcast will begin at 9.00am AEDT, Friday, November 20; 5.00pm EST,
Thursday, November 19, 2020. It can be accessed via
https://webcast.boardroom.media/mesoblast-limited/20201119/NaN5fb59c68f297810019932232
The archived webcast will be available on the
Investor page of the Company’s website: www.mesoblast.com
About Mesoblast Mesoblast Limited
(Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic
(off-the-shelf) cellular medicines. The Company has leveraged its
proprietary mesenchymal lineage cell therapy technology platform to
establish a broad portfolio of commercial products and late-stage
product candidates. Mesoblast has a strong and extensive global
intellectual property (IP) portfolio with protection extending
through to at least 2040 in all major markets. The Company’s
proprietary manufacturing processes yield industrial-scale,
cryopreserved, off-the-shelf, cellular medicines. These cell
therapies, with defined pharmaceutical release criteria, are
planned to be readily available to patients worldwide.
Remestemcel-L is being developed for inflammatory
diseases in children and adults including steroid-refractory acute
graft versus host disease and moderate to severe acute respiratory
distress syndrome. Mesoblast is completing Phase 3 trials for its
product candidates for advanced heart failure and chronic low back
pain. Two products have been commercialized in Japan and Europe by
Mesoblast’s licensees, and the Company has established commercial
partnerships in Europe and China for certain Phase 3
assets.
Mesoblast has locations in Australia, the United
States and Singapore and is listed on the Australian Securities
Exchange (MSB) and on the Nasdaq (MESO). For more information,
please see www.mesoblast.com, LinkedIn: Mesoblast Limited and
Twitter: @Mesoblast
Release authorized by the Chief Executive.
For further information, please contact:
Media Julie Meldrum T: +61 3 9639 6036
E:julie.meldrum@mesoblast.com |
Kristen Bothwell T: +1 917 613 5434 E:kbothwell@rubenstein.com |
|
|
Investors Schond Greenway T: +212 880 2060
E: schond.greenway@mesoblast.com |
Paul Hughes T: +61 3 9639 6036
E: paul.hughes@mesoblast.com |
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jul 2023 to Jul 2024